A Multi-Center, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo and Active Controlled, Parallel Group, Dose Range Study to Evaluate the Efficacy and Safety of LCZ696 Comparatively to Valsartan, and to Evaluate AHU377 to Placebo After 8 Week Treatment in Patients With Essential Hypertension.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Sacubitril (Primary) ; Sacubitril/valsartan (Primary) ; Valsartan
  • Indications Essential hypertension; Hypertension
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 04 Jul 2012 Planned patient number is 1560 as reported by European Clinical Trials Database record.
    • 16 Mar 2010 Results presented at the 59th Annual Scientific Session of the American College of Cardiology (ACC-2010).
    • 16 Mar 2010 Results published in the Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top